Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
T Cascone, WN William Jr.,A Weissferdt,CH Leung,HY Lin,A Pataer, MCB Godoy,BW Carter,L Federico,A Reuben, MAW Khan,H Dejima,A Francisco-Cruz,ER Parra,LM Solis,J Fujimoto,HT Tran,N Kalhor,FV Fossella,FE Mott,AS Tsao,G Blumenschein Jr.,X Le,J Zhang,F Skoulidis,JM Kurie,M Altan,C Lu,BS Glisson,LA Byers,YY Elamin,RJ Mehran,DC Rice,GL Walsh,WL Hofstetter,JA Roth,MB Antonoff,H Kadara,C Haymaker,C Bernatchez,NJ Ajami,RR Jenq,P Sharma,JP Allison,A Futreal,JA Wargo,II Wistuba,SG Swisher,JJ Lee,DL Gibbons,AA Vaporciyan,JV Heymach,B Sepesi immuneACCESS
关键词
neoadjuvant nivolumab,cell lung cancer,lung cancer,non-small
AI 理解论文
溯源树
样例
